Dec. 17 at 8:23 AM
$QTTB I'm 99.9% convinced now this company is in the process of being bought out.
Too much precedence in big pharma swooping in to grab distressed bios months after a failed trial.
Trillium failed and 23 cents. Pfizer swooped in and grabbed them for
$18.76/sh
Neuroderm failed and down to
$1+. Bought out for
$39
Elan failed and down to
$2.80. Then up over
$30 before the Perrigo buyout
There's another (can't recall name) that failed and Boehringer immed stepped in and grabbed them for a 300% premium
Just last yr, PRVB down to
$2 and immed bought out for
$24
This licensing deal with Akebia is now an asset on the books, and add to it their patent portfolio and this company is worth north of
$20 per share
It's coming and don't be surprised if it's by end of year
